secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001558370-23-018688
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios Q3 net loss narrows to $1.2M; secures FDA guidance for IMC-1 Phase 3
---------------------------------------------------------------------------

- Net loss $1.2M ($0.06/share) vs $2.6M ($0.28/share) in Q3 2022; cash $4.8M.
- R&D expenses fell to $0.4M from $1.6M on lower clinical trial costs.
- FDA guidance secured for IMC-1 Phase 3 in fibromyalgia; partnership discussions underway.
- Briefing materials submitted to FDA for IMC-2 IND to treat Long-COVID.
- Cash runway expected into Q3 2024 through expense management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/0001558370-23-018688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/tmb-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer